Check out your Company Bowl for anonymous work chats.
In its first credit rating, Sartorius received a solid investment grade rating today. The international rating agency S&P Global Ratings assigned a long-term issuer rating of BBB with a stable outlook. Read Press Release: https://srtrs.info/investment-grade-rating
Great Minds Think Alike. Greater Minds Think Together. Working on your next breakthrough in life science and bioprocessing? People think scientific progress is about facts, figures, and results. What really drives progress, however, are people. But you can’t do it alone. You need a partner you can trust. At Sartorius, we see what fuels our partners’ research, development, and production: Their current and future challenges. Their opportunities. Their ups and downs. And they can be sure of one thing: We’re in this together. We are the partner to simplify progress - now and in the future. Let’s start working together at www.sartorius.com/inthistogether #SimplifyingProgress #LifeSciences #bioprocessing
Have you browsed our open positions lately? Sartorius offers diverse opportunities in Sales, Services, R&D, and in other teams. If you find one that matches your expertise, take the chance to elevate your career to the next level and become part of our team: www.sartorius.com/careers
From Stay-at-Home mom to Key Account Manager – meet Rowena! After graduating in biochemistry and kicking-off a sales career, Rowena decided to focus on her family. Ignoring the voices that predicted she would regress professionally, she stayed home with her children for 15 years. Today, she is thriving as a Key Account Manager at Sartorius, helping our customers to accelerate research and find treatments for various diseases. How did she manage? Read the full story: https://srtrs.info/opu02
At today’s meeting, the Supervisory Board of Sartorius AG appointed Dr. Florian Funck as Chief Financial Officer (CFO) and member of the Sartorius Executive Board, effective April 1, 2024. He succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group.
Our manufacturing site in Bangalore, India, has taken a significant step toward reducing greenhouse gas emissions on-site. In a two-step process, the team successfully transitioned to 100% renewable power supply: Since 2022, approximately 1,500 solar panels have generated around 50% of the site's electricity consumption. The remaining electricity needs are now met by purchasing emission-free power from renewable sources. As a result of these efforts, a total of 70% of the site's overall energy consumption now comes from renewable sources, supporting the company's climate target of eliminating greenhouse gas emissions from purchased electricity, steam, heat, and cooling by 2030.
Calling all life science enthusiasts out there: We are hiring! Check out the latest opportunities for you to leave your mark in sales, services, R&D and other teams – and to be part of the solution to explore and manufacture new medications for diseases like cancer or Alzheimer’s. Interested? Come work with us: www.sartorius.com/careers
Sartorius maintains high profitability despite the expected temporary declines in the first half of 2023 After pandemic-related business and inventory buildup by customers had triggered extraordinary growth in previous years, the life science group Sartorius experienced temporary soft demand in both divisions throughout first half of 2023, as expected. Accordingly, the company recorded a decline in sales revenue in the first six months of the year and a lower but still relatively high profitability. Company management confirmed the full-year sales revenue and profitability outlook, which was adapted in mid-June.
Hello and welcome to all new colleagues at Polyplus. Some 270 new employees have joined the Sartorius team at the sites in France, Belgium, the U.S., and China today, following the closing of the acquisition. Together, we will continue to work towards our vision: to make better health more accessible to people around the world.
Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has successfully closed the acquisition of the French company Polyplus. The transaction was completed today, after receiving the required regulatory approvals. Polyplus is a leading provider of innovative technologies for cell and gene therapies. Transfection reagents developed and produced by Polyplus are key components in the manufacture of viral vectors. The company has been expanding its focus beyond this field through acquisitions in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening its portfolio for gene therapies as well as gene-modified cell therapies. Read Press Release: https://srtrs.info/l3l2m
